Table 1.

Clinical and biological characteristics of LEN-treated patients.

	Group A (VRD) (n = 7)	Group B (SCT) (n = 3)
Male/female	5/2	2/1
Age (range)	59 (50–67)	60 (48–65)
Myeloma subtype
IgG	5	2
IgA	3	1
Median immunoglobulin peak levels (range) (g/L)	29 (10.1–75.8)	19.8 (1.5–43.4)
Median β2 microglobulin levels (range) (mg/L)	3.1 (2.7–13.6)	2 (1.3–2.3)
LEN dose
Median no. of lenalidomide (LEN) cycles	13	12
10 mg/day	5	1
15 mg/day	2	2
Patient outcome
Remission	3	0
Relapse	4	2
Death	0	1

VRD, Velcade Revlimid Dexamethasone, SCT, stem-cell transplantation.